The personalized cancer vaccines market has seen considerable growth due to a variety of factors.
• The market for personalized cancer vaccines has seen robust growth lately. It is projected to expand from $242.29 billion in 2024 to $259.11 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 6.9%.
The significant growth observed previously is credited to progress in genomic studies, the creation of specialized treatments, improved knowledge of tumor immunology, advancements in vaccine technology, and the increasing evidence from clinical trials that validates their effectiveness.
The personalized cancer vaccines market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the market for personalized cancer vaccines is expected to witness robust expansion. The market size is poised to reach $336.03 billion in 2029, with a compound annual growth rate (CAGR) of 6.7%.
Factors like the progress in precision medicine, augmented funding for cancer research, surge in cancer cases, advancements in gene sequencing technologies, and heightened interest in customized treatment options are contributing to this forecast period growth. The future trends include the incorporation of artificial intelligence in vaccine development, breakthroughs in multi-antigen and neoantigen-centric vaccines, escalating utilization of liquid biopsies for tumor surveillance, proliferation of combination therapies, and a stronger emphasis on personalized therapy plans.
The personalized cancer vaccine market is expected to experience significant growth due to the increasing rates of cancer. Cancer, a group of diseases characterized by abnormal cell growth which can metastasize to other body parts, is becoming more prevalent due to factors such as aged populations, lifestyle shifts, environmental pollution, genetic inclinations, and advanced diagnostic methodologies. Personalized cancer vaccines play a vital role in combating the escalating rates of cancer. They do this by focusing on distinct tumor antigens exclusive to each individual, thereby boosting the immune system's capacity to identify and eradicate cancer cells. For example, as per data released by the Australian Institute of Health and Welfare, a governmental organization based in Australia, there was a marked increase in cancer diagnoses from 160,570 in 2022 to 164,694 in 2023. Hence, the mounting prevalence of cancer is fueling the expansion of the personalized cancer vaccine market.
The personalized cancer vaccinesmarket covered in this report is segmented –
1) By Treatment Type: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines
2) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Prostate Cancer, Cervical Cancer, Glioblastoma
3) By Mechanism Of Action: Tumor Associated Antigens (TAAs), Tumor Specific Antigens (TSAs), Somatic Mutations In Cancer Pharmacogenomics, Pharmacogenomics Towards Genomic Polymorphism, Other Mechanisms Of Action
4) By Route Of Administration: Injectables, Other Routes Of Administration
5) By End Use: Hospitals, Clinic, Other End Users
Subsegments:
1) By Preventive Cancer Vaccines: HPV Vaccines, Hepatitis B Vaccines, Combination Vaccines
2) By Therapeutic Cancer Vaccines: Dendritic Cell Vaccines, Peptide-Based Vaccines, DNA Vaccines, RNA Vaccines, Whole Cell Vaccines
Leading businesses in the personalized cancer vaccine market are concentrating on the development of innovative treatment options like personalized immunotherapy in order to increase precision in the treatment of specific cancer mutations. Personalized immunotherapy introduces specialized treatment methods that leverage the patient's distinct tumor attributes and genetic distinctions to enhance immune responses to cancer. For instance, UCLA Health, an American healthcare corporation, initiated a pioneering clinical trial in August 2024 to assess the safety and effectiveness of a cancer vaccine. The vaccine, created at UCLA, employs a tailored immunotherapy technique designed to target the H3 G34 mutation found in diffuse hemispheric gliomas, an extremely aggressive form of brain cancer common in young adults and adolescents. This technique uniquely uses dendritic cells to stimulate the immune system against the particular RNA disruptions brought on by this mutation. This strategy, which has shown potential efficacy in treating other cancers, seeks to enhance treatment results for patients who generally have limited treatment alternatives and reduced survival rates.
Major companies operating in the personalized cancer vaccines market are:
• Merck & Co Inc.
• GlaxoSmithKline Plc
• NEC Corporation
• Moderna Inc.
• Catalent Inc.
• UCLA Health
• Genetech Inc.
• NHS England
• CureVac AG
• Personalis Inc.
• Achilles Therapeutics Plc
• Healio
• Moffitt Corporation
• BioPharma APAC
• Celebrity Angels
• EpiVax Therapeutics Inc.
• Evaxion Biotech AS
• Geneos Therapeutics Inc.
• IFL Sciense
• ISA Pharmaceuticals BV
• Oxford Global
• Kintara Therapeutics
• VAXIMM Gmbh
North America was the largest region in the personalized cancer vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized cancer vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.